Pfenex Reports Results of Human Factors Study for its PF708 Candidate (biosimilar, teriparatide)

 Pfenex Reports Results of Human Factors Study for its PF708 Candidate (biosimilar, teriparatide)

Alvogen and Pfenex’ PF708 (biosimilar, teriparatide) Receives FDA’s Approval for the Treatment of Osteoporosis

  • The follow on study involves assessing of PF708 vs Forteo in 102 patients including 52 with osteoporosis and 50 with caregivers
  • The study demonstrated PF708 had fewer or equal user errors showing 33% and 17 % of critical tasks respectively further concluded that the study data of user interface of the FDA-approved PF708 product is noninferior to that of Forteo
  • PF708 is a mAb approved by the US FDA for treatment of osteoporosis in certain patients at high risk for fracture and is filled with RMA under biosimilar pathway referencing Forsteo

Click here to­ read full press release/ article | Ref: Pfizer | Image: Pharma World

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post